Soligenix awarded US patent for treating IBS with oral beclomethasone dipropionate.
M2 EQUITYBITES-19 May 2010-Soligenix awarded US patent for treating IBS with oral beclomethasone dipropionate(C)2010 M2 COMMUNICATIONS http://www.m2.com
Late-stage biopharmaceutical company Soligenix Inc (OTCBB:SNGX) has been granted a US patent for the treatment of irritable bowel syndrome (IBS) with oral beclomethasone dipropionate (BDP), the company said today.
The new patent number 7,704,985 is entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases".
Christopher J. Schaber PhD, president and CEO of Soligenix, commented: "There is an increasing awareness that IBS results in part from an inflammatory cascade in the GI tract, which makes it amenable to treatment with topically active steroids such as oral BDP."
He added: "We believe that our oral BDP formulations will have utility in other inflammatory GI diseases as well such as Graft-versus-Host disease (GVHD), radiation enteritis and Crohn's disease."
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||May 19, 2010|
|Previous Article:||Starbucks names Jeff Hansberry as President, Global Consumer Products and Foodservice.|
|Next Article:||Global Sources posts increased net income of USD2.6m in Q1 2010.|